XML 165 R152.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Information - Impairment (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Jun. 30, 2022 | Jun. 30, 2021
Asset Impairment Charges [Abstract] |  |
Impairment loss | $ 75,458 | $ 12,825
BioPharma |  |
Asset Impairment Charges [Abstract] |  |
Impairment loss | 64,600 |
Consumer Health |  |
Asset Impairment Charges [Abstract] |  |
Impairment loss | $ 10,800 |

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AssetImpairmentChargesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=aytu_BiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |